机制性静态模型能否支持药物相互作用研究的监管申报与说明书推荐?
该研究基于美国FDA不同申请类别中成功提交的生理药代动力学(PBPK)代表性案例,用相同数据与建模流程比较机制性静态模型与PBPK模型对药物相互作用(DDI)的预测。结果显示,以未结合平均稳态浓度作为调节剂驱动浓度时,静态模型预测的AUC比值与FDA审评中PBPK模型报告的结果大多可比。作者认为应鼓励使用最适合目的模型,将PBPK限于发挥其独特优势的场景,并触发对两种方法常规比较的讨论。
要点
- 机制性静态模型预测的AUC比值与FDA审评中PBPK模型结果大多可比。
- 以未结合平均稳态浓度作为调节剂驱动浓度可得出与PBPK相似的DDI风险结论。
- 建议按目的选择模型,PBPK限用于剂量错峰、转运体、人群外推等场景。
核心结论
- 在相同输入数据下,机制性静态模型预测的AUC比值与FDA审评中PBPK模型报告结果大多可比,可支持监管申报的DDI风险评估。
研究设计与样本
- 研究选取美国FDA不同申请类别下成功提交PBPK的代表性案例,采用与FDA临床药理学审评相同的数据和建模流程进行机制性静态模型DDI预测。
主要发现
- 机制性静态模型预测的AUC比值在全部代表性案例中与FDA审评中PBPK模型报告结果大多可比。
- 使用未结合平均稳态浓度作为调节剂驱动浓度时,静态模型对非动态DDI风险指标可得出与PBPK建模相同的结论。
临床怎么用
- 可根据预期目的选择机制性静态模型或PBPK模型进行DDI风险评估,以优化监管申报资源。
- PBPK模型宜限用于发挥其独特优势的场景,如剂量错峰、摄取与外排转运体评估、人群外推及多机制DDI影响评估。
局限性
- 研究仅基于代表性案例,未涵盖所有药物或DDI场景。
- 结论限于非动态DDI风险指标(如AUC比值),未评估动态浓度变化对DDI风险评估的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Mechanistic static and dynamic physiologically based pharmacokinetic models are used in clinical drug development to assess the risk of drug-drug interactions (DDIs). Currently, the use of mechanistic static models is restricted to screening DDI risk for an investigational drug, while dynamic physiologically based pharmacokinetic models are used for quantitative predictions of DDIs to support regulatory filing. As physiologically based pharmacokinetic model development by sponsors as well as a review of models by regulators require considerable resources, we explored the possibility of using mechanistic static models to support regulatory filing, using representative cases of successful physiologically based pharmacokinetic submissions to the US Food and Drug Administration under different classes of applications. METHODS: Drug-drug interaction predictions with mechanistic static models were done for representative cases in the different classes of applications using the same data and modelling workflow as described in the Food and Drug Administration clinical pharmacology reviews. We investigated the hypothesis that the use of unbound average steady-state concentrations of modulators as driver concentrations in the mechanistic static models should lead to the same conclusions as those from physiologically based pharmacokinetic modelling for non-dynamic measures of DDI risk assessment such as the area under the plasma concentration-time curve ratio, provided the same input data are employed for the interacting drugs. RESULTS: Drug-drug interaction predictions of area under the plasma concentration-time curve ratios using mechanistic static models were mostly comparable to those reported in the Food and Drug Administration reviews using physiologically based pharmacokinetic models for all representative cases in the different classes of applications. CONCLUSIONS: The results reported in this study should encourage the use of models that best fit an intended purpose, limiting the use of physiologically based pharmacokinetic models to those applications that leverage its unique strengths, such as what-if scenario testing to understand the effect of dose staggering, evaluating the role of uptake and efflux transporters, extrapolating DDI effects from studied to unstudied populations, or assessing the impact of DDIs on the exposure of a victim drug with concurrent mechanisms. With this first step, we hope to trigger a scientific discussion on the value of a routine comparison of the two methods for regulatory submissions to potentially create a best practice that could help identify examples where the use of dynamic changes in modulator concentrations could make a difference to DDI risk assessment.
引用
- Gomez-Mantilla JD, Huang F, Peters SA, et al. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations? Clin Pharmacokinet. 2023. PMID: 36752991. doi:10.1007/s40262-022-01204-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。